About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Novel Treatment Effective to Treat Symptoms of Parkinsonís Disease

by Megha Ramaviswanathan on January 29, 2018 at 5:46 PM
Font : A-A+

Novel Treatment Effective to Treat Symptoms of Parkinsonís Disease

Existing drug treatment for Parkinson's disease may induce motor complications like dyskinesias that causes abnormal involuntary movements and reduce the effectiveness of restoring mobility. Scientists at Yerkes National Primate Research Center, Emory University, have been observing the origin of these abnormal responses in a nonhuman primate model of Parkinson's and have successfully found a way for controlling them. The results, which will be important for developing new treatment options, are published in Cell Reports.

Neuroscientists think dyskinesias come from fluctuations in dopamine, the neuronal messenger whose production is lost in the brains of people who have Parkinson's disease. The standard drug levodopa restores dopamine, but sometimes, in the process of achieving symptom relief, dopamine levels become too high, and responses are unstable.

Advertisement


Research team led by Stella Papa, MD, showed striatal projection neurons (SPN), which become hyperactive when nearby dopamine-producing neurons degenerate, could be controlled by certain drugs, reducing the rate of unstable responses to dopamine that cause dyskinesias. The striatum is part of the basal ganglia, the region of the brain most visibly impacted by Parkinson's.

"Our focus was to prove SPN hyperactivity plays an important role and that glutamate signals are a major contributor," says Papa, associate professor of neurology at Emory University School of Medicine and a Yerkes scientist. "Knowing this mechanism may serve to develop different therapeutic strategies: pharmacological treatments or gene therapies."
Advertisement

The first author of the paper is former Yerkes researcher Arun Singh, PhD, now at University of Iowa. Laboratories in Emory's Department of Pharmacology made significant contributions to this work, especially the group Stephen Traynelis, PhD, leads; Dr. Traynelis had a key role in the study. Annalisa Scimemi at SUNY Albany also contributed to the study.

The research team tested whether the drug LY235959 (an NMDA receptor antagonist) or NBQX (an AMPA receptor antagonist) could control SPN hyperactivity and dyskinesia symptoms in Parkinson's model monkeys. The nonhuman primate model of Parkinson's uses the neurotoxin MPTP, which destroys dopamine-producing neurons.

Both drugs interfere with signals by the neurotransmitter glutamate. In the presence of levodopa, the drugs had calming effects both in single cell SPN recordings and when the drugs were infused into monkeys' basal ganglia. After lowering the SPN firing frequency by 50 percent, the response to dopamine stabilizes and abnormal movements are markedly diminished, Papa says.

She notes the particular drugs used are not ideal for use in humans, but they do reveal mechanisms behind dyskinesias, insights that will be valuable to advance the research and develop new treatments with improved effectiveness for people who have Parkinson's disease.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Coffee May Help You Fight Endometrial Cancer
Fermented Skin Care
Television Binge-Watching May Boost the Risk of Deadly Blood Clots
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Nutritional Management of Parkinsons disease 

Recommended Reading
LRRK Gene Provides Insight into Development of Parkinsonís Disease
LRRK gene knockout experiments in mice revealed the physiological role of the gene that is commonly ...
People With Restless Sleep Disorder at High Risk for Parkinsonís Disease
Patients with the rapid eye movement sleep behaviour disorder lack dopamine and are at increased ......
Parkinsonís Disease Shows Changes in Brainstem
Changing mitochondrial DNA in the pedunculopontine cholinergic neurons can be possible targets for ....
Genetic Mutation Identified in Parkinsonís Disease Patients
The novel ACMSD mutation identified in parkinson's disease patients and this new mutation in the ......
Nutritional Management of Parkinsons disease
Parkinson's disease is a brain disorder which leads to many other related effects. Nutrition plays a...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)